Evidence map›Paper›PMID 23466651›Full record

ArticleAnti-cancer drugs2013

Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.

Ziyan Lu, Yufeng Tian, Helen R Salwen, Alexandre Chlenski, Lucy A Godley, J Usha Raj, Qiwei Yang

Open access · greenAbstract read
In one paragraph

Article in Anti-cancer drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Increasing autophagy activity suppressesAmerican journal of cancer research · 2026
    Article
  5. Review
  6. Review
  7. Epigenetic Dysregulation inInternational journal of molecular sciences · 2023
    Review
  8. Histone Methyltransferases G9a/International journal of molecular sciences · 2023
    Article
  9. Article
  10. Review
  11. Neuroblastoma and the epigenome.Cancer metastasis reviews · 2021
    Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. TargetingFrontiers in oncology · 2020
    Review
  17. Review
  18. Targeting of epigenetic regulators in neuroblastoma.Experimental & molecular medicine · 2018
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Ziyan LuDepartment of Pediatrics, College of Medicine, University of Illinois at Chicago, Chicago, Illinois 60612, USA.
Yufeng Tian
Helen R Salwen
Alexandre Chlenski
Lucy A Godley
J Usha Raj
Qiwei Yang
University of Chicago · USUniversity of Illinois Chicago · US

Funding

Mechanisms of cGMP-Mediated Vasodilation in Perinatal LungR01HL059435 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RAJ, J. USHA · 1998 to 2010
$3.9M
Functional Heterogeneity of Pulmonary Arteries and VeinsR01HL075187 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RAJ, J. USHA · 2003 to 2011
$3.8M
Role of microRNA-17-92 and PDLIM5 Signaling in Pulmonary Arterial HypertensionR01HL123804 · NHLBI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI RAJ, J. USHA, ZHOU, GUOFEI · 2015 to 2018
$1.6M
NHLBI NIH HHS R01 HL059435NHLBI NIH HHS R01 HL075187NHLBI NIH HHS R01 HL123804
6 · The paper itself

Abstract

Neuroblastoma (NB), a childhood neoplasm arising from neural crest cells, is characterized by a diversity of clinical behaviors ranging from spontaneous remission to rapid tumor progression and death. In addition to genetic abnormalities, recent studies have indicated that epigenetic aberrations also contribute toward NB pathogenesis. However, the epigenetic mechanisms underlying the pathogenesis of NB are largely unknown. Inhibition of euchromatic histone-lysine N-methyltransferase 2 (EHMT2) was evaluated through the measurement of H3K9Me2 levels. Cell proliferation was examined by cell counting in human NB cell lines (LA1-55n, IMR-5, and NMB). The RNA expression of EHMT2, MYCN, and p21 was measured by real-time PCR. The expression of PCNA, MYCN, p53, cyclinD1, H3, H3K27M2, and H3K9Me2 was examined by western blot analysis. In-vitro invasion and the effects of the EHMT2 inhibitor (BIX-01294) were assessed in the Transwell chamber assay. Caspase 3 and 8 activities were measured using a Caspase-Glo assay kit. The level of overall DNA methylation was measured by liquid chromatography-mass spectroscopy. BIX-01294, a specific inhibitor of EHMT2 (a key enzyme for histone H3 dimethylation at lysine-9), specifically decreases the overall H3K9Me2 level but not H3K27Me2. The inhibition of EHMT2 decreased the proliferation of NB cells and induced apoptosis by increasing caspase 8/caspase 3 activity. BIX-01294 inhibited NB cell mobility and invasion. This was accompanied by a decreased expression of the MYCN oncogene. Inhibition of EHMT2 enhanced a doxorubicin-induced inhibitory effect on cell proliferation. Finally, EHMT2 inhibition modulated overall DNA methylation levels in NB cells. Our results show that histone-lysine methylation is involved in cell proliferation, apoptosis, cell invasion, and overall DNA methylation in human NB cells. Further understanding of this mechanism may provide an insight into the pathogenesis of NB progression and lead to novel treatment strategies.

Indexed as

DNA MethylationApoptosisAzepinesCaspase 3Caspase 8Cell Line, TumorCell MovementCell ProliferationCyclin D1DoxorubicinEnzyme InhibitorsEpigenesis, GeneticGene Expression Regulation, NeoplasticHistocompatibility AntigensHistone-Lysine N-MethyltransferaseHumansAzepinesBIX 01294CASP8 protein, humanCaspase 3Caspase 8CCND1 protein, humanCyclin D1DoxorubicinEHMT2 protein, humanEnzyme InhibitorsHistocompatibility AntigensHistone-Lysine N-MethyltransferaseMYCN protein, humanN-Myc Proto-Oncogene ProteinNuclear ProteinsOncogene ProteinsQuinazolines

Identifiers

PMID23466651
PMCPMC3649845
OpenAlexW1970972194

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.